Phaseline

Companies › Jiangxi Qingfeng Pharmaceutical

Jiangxi Qingfeng Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Infectious disease; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GP681
Neuraminidase inhibitor
–Phase 3Influenza, Human; InfluenzaJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06573008GP681Phase 3Influenza, HumanInfectious diseaseDec 2025
NCT06574503GP681Phase 3InfluenzaInfectious diseaseJul 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Laboratorio Farmaceutico SIT srl Zero Point Five Therapeutics Lallemand Pharma Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) MicuRx

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.